Saag KG, et al. - In this 24-month randomized, double-blind, double-dummy trial, researchers analyzed 795 subjects of ≥18 years of age receiving ≥7.5 mg daily prednisone or equivalent for <3 months (glucocorticoid-initiating) or ≥3 months (glucocorticoid-continuing) before the screening to compare the efficacy of denosumab vs risedronate in osteoporosis (glucocorticoid-induced). Investigators observed the superiority of denosumab to risedronate in increase in lumbar spine and total hip BMD among glucocorticoid-initiating subjects ie, 24-month lumbar spine: 6.2% vs 1.7%; 24-month total hip: 3.1% vs 0.0% whereas glucocorticoid-continuing subjects ie, 24-month lumbar spine: 6.4% vs 3.2% and 24-month total hip: 2.9% vs 0.5%. They observed comparable adverse effects, serious adverse events including infections, and fractures between the treatment groups.